Home / 2020 / February
 

Year end report January to December 2019

  • -

Peptonic Medical AB (publ) org nr 556776-3064 (www.spotlightstockmarket.com , ticker: PMED). 2019 fourth quarter (Oct-Dec) Net sales of products KSEK 394 (263) Gross profit KSEK 321 (137), Gross margin 81% (52%) Operating

Read More

Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.